Global Pulmonary Drug Delivery Systems Market By Product Type (Dry Powder Inhaler (Single-dose Inhaler and Multi-dose Inhaler), Metered Dose Inhaler (Manually-actuated Pressurized Inhaler and Breath-actuated Pressurized Inhaler), Nebulizer (Jet Nebulizer, Ultrasonic Wave Nebulizer, and Vibrating Mesh Nebulizer), and Accessories), By Application (Cystic Fibrosis, Asthma, Allergic Rhinitis, COPD, and Others), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and E-Commerce), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

The Global Pulmonary Drug Delivery Systems Market size is expected to be worth around USD 97.8 billion by 2033 from USD 56.2 billion in 2023, growing at a CAGR of 5.7% during the forecast period 2024 to 2033.

The rising prevalence of respiratory diseases is expected to boost the market during the forecast period. There is a growing need for targeted and efficient drug delivery systems. Advances in technology and device engineering have opened up new opportunities for innovation in pulmonary drug delivery systems. The growing trend toward personalized medicine and the need to reduce side effects have fueled the demand for such drug delivery systems. The increasing geriatric population and the increasing adoption of home healthcare devices are creating new avenues for market growth.

Lifestyle changes are increasingly recognized as a significant contributor to various chronic disorders, including diabetes, functional gastrointestinal disorders, eczema, arthritis, asthma, cancer, and chronic obstructive pulmonary disease (COPD). As the global prevalence of these chronic conditions rises, the demand for effective treatments is expected to drive market growth over the forecast period.

For example, according to the September 2022 Global Impact of Respiratory Disease report by the Forum of International Respiratory Societies (FIRS), an estimated 200 million people worldwide suffer from COPD, with approximately 3.2 million deaths annually, making it the third leading cause of death globally. Additionally, in 2020, more than 2.2 million new cases of lung cancer were reported, resulting in 1.8 million deaths, with lung cancer accounting for 1 in 4 cancer-related deaths globally.

In addition, the rapid growth in air pollution all across the globe, particularly in the developing economies caused by urbanization and industrialization is leading to a large number of people suffering from lung diseases and having breathing problems. This problem becomes particularly severe among elderly people. In August 2021, according to the data issued by IQAir, the US AQI value was 74 for Mexico City, indicating “Moderate” air pollution levels at the start of 2021.

Key Takeaways

• Market Size: Pulmonary Drug Delivery Systems Market size is expected to be worth around USD 97.8 billion by 2033 from USD 56.2 billion in 2023.
• Market Growth: The market growing at a CAGR of 5.7% during the forecast period 2024 to 2033.
• Product Type Analysis: The product type segment is divided into dry powder inhaler, metered dose inhaler, nebulizer, and accessories, with metered dose inhalers taking the lead in 2023 with a market share of 61.2%.
• Application Analysis: Asthma held a significant share of 36.7% due to the increasing prevalence of asthma globally
• Distribution Channel Analysis: The hospital pharmacy segment had a tremendous growth rate, with a revenue share of 45.4%
• Regional Analysis: North America dominated the market with the highest revenue share of 41.2%
• Technology Advancements: Innovations in inhaler devices and nebulizers, including smart inhalers and portable nebulizers, are enhancing drug delivery efficiency and patient compliance.
• Challenges: High costs of advanced devices and regulatory hurdles may limit market expansion, particularly in developing regions.

Product Type Analysis

The metered dose inhalers segment led in 2023, claiming a market share of 61.2% owing to its widespread adoption and proven efficacy in treating respiratory diseases. The metered dose inhalers are a popular choice among patients and healthcare providers due to their ease of use, portability, and affordability.

The segments benefit from advancements in formulation technology, leading to more efficient and environmentally friendly propellants. Additionally, the introduction of generic and branded metered dose inhalers expands treatment options and drives market growth.

Application Analysis

Asthma held a significant share of 36.7% due to the increasing prevalence of asthma globally, driving demand for effective treatment options. Rising awareness about asthma management and growing adoption of preventive measures fuel market growth. Advances in inhaler technologies, such as smart inhalers and breath-activated devices, improve patient adherence and outcomes, further contributing to the segment’s expansion.

Furthermore, the increasing focus on personalized medicines and targeted treatments for severe asthma patients is likely to create profitable projections for the growth of this segment in the forecast period.

Distribution Channel Analysis

The hospital pharmacy segment had a tremendous growth rate, with a revenue share of 45.4% owing to the increasing demand for efficient and effective treatment of respiratory diseases in hospital settings. Rising hospital admissions for respiratory conditions drive the need for advanced pulmonary drug delivery systems.

Hospital pharmacies benefit from the adoption of innovative technologies, such as nebulizers and ventilators, to improve patient outcomes. Growing investments in hospital infrastructures and pharmacy services also contribute to segment growth.

Key Market Segments

By Product Type

• Dry Powder Inhaler
  • Single-dose Inhaler
  • Multi-dose Inhaler
• Metered Dose Inhaler
  • Manually-actuated Pressurized Inhaler
  • Breath-actuated Pressurized Inhaler
• Nebulizer
  • Jet Nebulizer
  • Ultrasonic Wave Nebulizer
  • Vibrating Mesh Nebulizer
• Accessories

By Application

• Cystic Fibrosis
• Asthma
• Allergic Rhinitis
• COPD
• Others

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• E-Commerce

Drivers

Growing Prevalence of Respiratory Issues

The growing prevalence of respiratory issues such as asthma, COPD, and cystic fibrosis are expected to create lucrative prospects for the market during the forecast period. It increases the demand for effective and targeted treatment options. As the number of patients with respiratory diseases rises, so does the need for innovative drug delivery systems that can provide efficient and precise medication administration.

Pulmonary drug delivery systems offer a direct route to the lungs, allowing for higher drug concentrations and faster onset of action, making them an attractive solution for respiratory disease management. As per the report published by the Australian Bureau of Statistics in February 2024, the deaths caused by respiratory ailments in February 2024 were 4% higher than what they were in 2023, which was 16.4%. Deaths from diseases such as pneumonia, influenza, and chronic lower respiratory ailments were all greater in February 2024 than in 2023 or 2022.

Restraints

High Cost of Pulmonary Drug Delivery Systems

The high cost of pulmonary drug delivery systems, including development, manufacturing, and maintenance, is projected to impede the market during the assessment period by limiting accessibility and adoption. High-priced systems deter customers belonging to low- to mid-income households, particularly in emerging economies.

Additionally, the costly nature of these systems can lead to reduced reimbursement rates from insurance providers, further hindering market expansion. Furthermore, the high cost of R&D, regulatory approvals, and clinical trials also discourage new market players, hindering innovation.

Opportunities

Growing Awareness of Pulmonary Ailments

The growing awareness of pulmonary ailments such as asthma and COPD creates an opportunity for the pulmonary drug delivery systems market by increasing demand for effective treatment options. As patients and healthcare providers become more informed about respiratory diseases, the need for targeted and efficient drug delivery systems grows. This awareness drives the adoption of pulmonary drug delivery systems, further fueling the market.

Moreover, increased awareness leads to early diagnosis and treatment, thereby expanding the patient base for these systems. In the year 2023, the American Lung Association started its Research Institute and increased its research investment to US$ 25 million. Simultaneously, the organization is continually developing and enhancing support resources for the patients of lung cancer and their caregivers.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic and geopolitical factors exert a significant influence on the Pulmonary Drug Delivery Systems market, shaping its growth trajectory and dynamics. Macroeconomic factors such as government funding, trade policies, and economic growth impact the pulmonary drug delivery systems market, with positive aspects including increasing funding for healthcare and research.

Geopolitical factors such as global collaborations and agreements facilitate the exchange of ideas and technologies, driving innovation. However, trade wars, tariffs, and economic downturns can limit market growth reducing investments and demand. A stable economic environment and favorable trade policies can boost the market in the coming years.

Latest Trends

Technological Advancements in Pulmonary Drug Delivery Systems

The technological advancements in pulmonary drug delivery systems are projected to create profitable projects for the market in the years to come, driven by innovations in device design, material science, and digital technologies. Developments in aerosol science and formulation technology have improved drug delivery efficiency and efficacy.

In April 2022, GlaxoSmithKline Pharmaceuticals introduced Trelegy Ellipta, a once-daily single-inhaler triple therapy (SITT) for treating chronic obstructive pulmonary diseases (COPD) in India. Smart inhalers with sensors and digital connectivity are emerging, enabling real-time monitoring and personalized treatment.

Regional Analysis

North America is leading the Pulmonary Drug Delivery Systems Market

North America dominated the market with the highest revenue share of 41.2% owing to the rising prevalence of respiratory diseases such as asthma, COPD, and others. There have been significant advancements in the inhaler technologies, such as smart inhalers and breath-activated devices. This is leading to better patient adherence and outcomes.

Numerous key players are launching new products, such as generic and branded metered dose inhalers, which is further driving the market’s growth. For instance,  Glenmark launched a bioequivalent version of the Tiotropium Bromide dry powder inhaler (DPI) for COPD treatment in Spain in October 2021. The company now sells the powder under the brand called Tavulus.

The Asia Pacific region is expected to experience the highest CAGR during the forecast period

Asia Pacific is expected to grow with the fastest CAGR owing to the surge in the prevalence of respiratory diseases and rising healthcare expenditure. The region’s large patient pool, improving healthcare infrastructure, and increasing adoption of advanced technologies are projected to provide substantial propulsion to the market in this region. Another major factor responsible for market growth in this region is the rise of the geriatric population.

Elderly people are prone to pulmonary ailments and thus create a strong customer base for the key market players. As per the data published by the United Nations Population Fund in 2022, approximately 59% of the total number of people residing in Japan falls within the 15-64 age group. Furthermore, 29% of them are aged 65 years and above.

Key Regions and Countries

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Russia
• Netherland
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• Australia
• New Zealand
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Rest of MEA

Key Players Analysis

The major players in the Pulmonary Drug Delivery Systems market are actively engaged in the development and introduction of innovative products, as well as implementing strategic initiatives aimed at enhancing their competitive positioning.

For instance, in March 2022, the US FDA approved the first generic version of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. Symbicort is used for asthma treatment in patients aged six years and older, as well as for maintaining airflow obstruction and reducing exacerbations in COPD patients.

Top Key Players

• Teva Pharmaceutical Industries Ltd.
• RIGImmune
• Philips Respironics
• PARI GmbH
• Omron Healthcare, Inc.
• GlaxoSmithKline PLC
• Gilbert Technologies
• Hoffmann-La Roche AG
• Boehringer Ingelheim GmbH
• Aptar Pharma
• AstraZeneca PLC
• 3M Healthcare

Recent Developments

• Philips Respironics (January 2024): Philips Respironics finalized a consent decree with the U.S. Department of Justice and the FDA. This agreement is part of ongoing efforts to ensure compliance with regulatory standards and improve safety in their pulmonary drug delivery products​.
• Omron Healthcare, Inc. (March 2024): Omron launched a smart nebulizer with integrated digital health features. This device not only administers drugs efficiently but also tracks usage and provides feedback to patients and healthcare providers, enhancing treatment outcomes​.
• GlaxoSmithKline PLC (April 2024): GSK expanded its portfolio with the launch of a new dry powder inhaler, designed to provide better patient adherence through ease of use and dose accuracy. This product is expected to strengthen GSK’s leadership in the pulmonary drug delivery market​.
• Gilbert Technologies (2022): Gilbert Technologies announced a strategic partnership with a major pharmaceutical company to co-develop a new inhaler device. This collaboration aims to improve drug delivery efficiency and expand Gilbert’s footprint in the pulmonary drug delivery market​.
• Teva Pharmaceutical Industries Ltd. (May 2024): Teva received FDA approval for two new RespiClick maintenance inhalers, expanding their portfolio of asthma treatments. These inhalers enhance patient compliance through their easy-to-use design and are expected to strengthen Teva’s position in the pulmonary drug delivery market​.

Report Scope